Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, growing 4.38 percent year-over-year but missing analyst consensus estimates of $94.0 million. The company posted a non-GAAP net loss of $16.2 million, or $(0.58) per share, widening significantly from the prior year’s non-GAAP profit of $0.07 per share. Citing processing delays in its revenue cycle management and billing system transition, Fulgent lowered its full-year 2026 revenue guidance to a range of $330.0-$340.0 million, signaling near-term headwinds for shareholders despite modest top-line growth.

Financial Performance Overview

The quarter’s results highlight a divergence between operational scale and profitability. While revenue expanded sequentially by 20.1 percent, gross margin contracted sharply. GAAP gross profit stood at $25.7 million, representing a GAAP gross margin of 30.1 percent, down from 42.1 percent in the same period last year. Non-GAAP gross margin also declined to 31.3 percent from 44.2 percent. The company incurred a GAAP net loss of $29.5 million, or $(1.05) per share, driven by higher operating expenses and equity-based compensation.

Operational Updates and Cash Position

Fulgent continued to execute on its strategic initiatives, including the expansion of its AI portfolio and digital pathology integration, which management stated is improving efficiency and quality. The company also presented encouraging Phase 2 data for its therapeutic candidate FID-007 at the 2026 American Society of Clinical Oncology (ASCO) meeting.

On the balance sheet, Fulgent ended the second quarter with $551.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.1 million delayed by IRS resource constraints. During the quarter, the company repurchased approximately 1.5 million shares for $23.8 million. Year-to-date, Fulgent has used $63.9 million for stock repurchases, reducing its share count by 4.1 million shares.

Outlook and Guidance Revision

Management revised its full-year 2026 outlook downward due to the billing system transition issues. Key updated guidance figures include:

• Revenue: $330.0-$340.0 million (previously higher)
• Non-GAAP Loss: Approximately $63.0-$67.0 million
• Non-GAAP Loss Per Share: Approximately $(2.22)-$(2.35), reflecting the impact of share repurchases
• Cash Position: Approximately $610.0 million, assuming receipt of the $106.1 million tax refund and no further repurchases

Chief Financial Officer Paul Kim noted that the company is working to remedy the billing collection rate issue and remains confident in the fundamental strength of its business. The revised per-share loss guidance accounts for the reduced share base resulting from the ongoing repurchase program.

What the Numbers Show

The data reveals a significant margin compression trend that outpaces revenue growth. While sequential revenue growth of 20.1 percent indicates underlying demand, the drop in GAAP gross margin from 42.1 percent to 30.1 percent suggests rising cost pressures or mix shifts not yet offset by scale. Furthermore, the divergence between the modest revenue miss (9.16 percent below consensus) and the substantial earnings deterioration highlights the sensitivity of Fulgent’s bottom line to operational execution costs, particularly during periods of IT infrastructure transition.

Fulgent Genetics (NASDAQ: FLGT) has issued downward revisions to its full-year financial guidance for FY2026, signaling a more challenging fiscal year than previously anticipated. The company lowered its adjusted earnings per share (EPS) guidance to a range of $(2.35) to $(2.22), a significant widening of the expected loss compared to its prior internal estimate of $(1.59). This revised outlook also falls short of the analyst consensus estimate of $(1.55), indicating that market expectations were already optimistic relative to the company’s latest internal projections.

Alongside the EPS revision, Fulgent Genetics trimmed its top-line revenue forecast for FY2026. The company now expects sales to fall between $330.000 million and $340.000 million, down from the previously communicated target of $350.000 million. This adjusted revenue band also underperforms the broader market expectation, with analysts having estimated FY2026 sales at $351.900 million. The simultaneous downgrade in both profitability and revenue metrics suggests headwinds affecting the company’s operational performance across multiple dimensions.

Key Financial Metrics Revised

The following table outlines the changes in Fulgent Genetics’ FY2026 guidance against prior internal estimates and external analyst consensus:

The divergence between the new guidance and analyst estimates is notable. While analysts had anticipated a loss of $(1.55) per share, the company’s own revised projection points to a substantially deeper loss, with the midpoint of the new range approximately $0.77 lower than the street estimate. Similarly, the revenue miss implies a potential shortfall of up to $21.9 million against analyst expectations if the lower end of the guidance range materializes.

What the Numbers Show

The magnitude of the EPS revision highlights a deterioration in margin dynamics or higher-than-expected cost structures within the business. By lowering the EPS guidance from $(1.59) to a range centered around $(2.28), Fulgent Genetics is effectively projecting an additional loss burden of nearly $0.70 per share beyond what it had internally planned. When combined with the revenue cut, this suggests that the company may be facing pressure on both the top line—through slower demand or pricing challenges—and the bottom line, potentially due to fixed cost absorption issues or increased operating expenses. Investors should monitor subsequent quarterly reports for clarity on whether these trends are temporary or indicative of a structural shift in the company’s financial trajectory.